Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials

被引：0
|
作者：
Rashbaum, B. [1 ]
Lucasti, C. [2 ]
Mounzer, K. [3 ]
Melbourne, K. [4 ]
Kwon, P. [4 ]
Piontkowsky, D. [4 ]
机构：
[1] Capital Med Associates PC, Washington, DC USA
[2] South Jersey Infect Dis, Somers Point, NJ USA
[3] Philadelphia FIGHT, Philadelphia, PA USA
[4] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL THERAPY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P25
引用
收藏
页码：A44 / A45
页数：2
相关论文
共 50 条
  • [41] Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1-Infected Subjects: 48 Weeks Data
    Mills, A.
    Crofoot, G.
    Ortiz, R.
    Rashbaum, B.
    Towner, W.
    Ward, D.
    Brinson, C.
    Kulkarni, R.
    Garner, W.
    Ebrahimi, R.
    Cao, H.
    Cheng, A.
    Szwarcberg, J.
    HIV CLINICAL TRIALS, 2014, 15 (02): : 51 - 56
  • [42] A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results
    Rockstroh, Juergen K.
    DeJesus, Edwin
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Plummer, Andrew
    Abram, Michael
    Cheng, Andrew K.
    Fordyce, Marshall W.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (05) : 483 - 486
  • [43] Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment
    Martorell, C.
    Ward, D.
    Short, W. S.
    Ramgopal, M.
    Das, M.
    Nguyen-Cleary, T.
    Shave, A.
    McCallister, S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S177 - S177
  • [44] 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
    Porter, Danielle P.
    Kulkarni, Rima
    Fralich, Todd
    Miller, Michael D.
    White, Kirsten L.
    HIV CLINICAL TRIALS, 2015, 16 (01): : 30 - 38
  • [45] Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting
    Mete, Bilgul
    Gunduz, Alper
    Karaosmanoglu, Hayat Kumbasar
    Gumuser, Fatma
    Bolukcu, Sibel
    Yildiz, Dilek Sevgi
    Aydin, Ozlem Altuntas
    Bilge, Bilgenur
    Dokmetas, Ilyas
    Tabak, Fehmi
    AFRICAN HEALTH SCIENCES, 2021, 21 (04) : 1593 - 1602
  • [46] Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
    Baldin, G.
    Ciccullo, A.
    Capetti, A.
    Rusconi, S.
    Sterrantino, G.
    Cossu, M. V.
    Giacomelli, A.
    Lagi, F.
    Latini, A.
    Bagella, P.
    De Luca, A.
    Di Giambenedetto, S.
    Madeddu, G.
    HIV MEDICINE, 2019, 20 (02) : 164 - 168
  • [47] Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected
    Gallant, Joel
    Brunetta, Jason
    Crofoot, Gordon
    Benson, Paul
    Mills, Anthony
    Brinson, Cynthia
    Oka, Shinichi
    Cheng, Andrew
    Garner, Will
    Fordyce, Marshall
    Das, Moupali
    McCallister, Scott
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (03) : 294 - 298
  • [48] Resistance profile analysis of treatment-experienced HIV-1-infected patients switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV)
    Margot, Nicolas
    Ram, Renee
    Das, Moupali
    Fordyce, Marshall
    McCallister, Scott
    Miller, Michael
    Callebaut, Christian
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [49] Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
    Kuo, Po-Hsien
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Wu, Pei-Ying
    Liu, Wen-Chun
    Hung, Chien-Ching
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 : 71 - 77
  • [50] Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
    Clumeck, Nathan
    Molina, Jean-Michel
    Henry, Keith
    Gathe, Joseph
    Rockstroh, Juergen K.
    DeJesus, Edwin
    Wei, Xuelian
    White, Kirsten
    Fordyce, Marshall W.
    Rhee, Martin S.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E121 - E124
12345